Fluocinolone Acetonide
Fluocinolone Acetonide structure
|
Common Name | Fluocinolone Acetonide | ||
|---|---|---|---|---|
| CAS Number | 67-73-2 | Molecular Weight | 452.488 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 578.5±50.0 °C at 760 mmHg | |
| Molecular Formula | C24H30F2O6 | Melting Point | 267-269 °C(lit.) | |
| MSDS | Chinese USA | Flash Point | 303.7±30.1 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
J. Sci. Ind. Res. 65(10) , 808, (2006) Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between preclinical and clinical findings of liver toxicity. We hypothesized that the DILI types (hepatotoxic side effects) seen in the clinic can be tra... |
|
|
Convenient QSAR model for predicting the complexation of structurally diverse compounds with β-cyclodextrins
Bioorg. Med. Chem. 17 , 896-904, (2009) This paper reports a QSAR study for predicting the complexation of a large and heterogeneous variety of substances (233 organic compounds) with beta-cyclodextrins (beta-CDs). Several different theoretical molecular descriptors, calculated solely from the mole... |
|
|
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Bioorg. Med. Chem. 18 , 2225-31, (2010) There are many of pathogen parasite species with different susceptibility profile to antiparasitic drugs. Unfortunately, almost QSAR models predict the biological activity of drugs against only one parasite species. Consequently, predicting the probability wi... |
|
|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
J. Med. Chem. 51 , 6740-51, (2008) The work provides a new model for the prediction of the MAO-A and -B inhibitor activity by the use of combined complex networks and QSAR methodologies. On the basis of the obtained model, we prepared and assayed 33 coumarin derivatives, and the theoretical pr... |
|
|
Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants.
Cochrane Database Syst. Rev. 4 , CD002311, (2012) Bronchopulmonary dysplasia (BPD), defined as oxygen dependence at 36 weeks postmenstrual age (PMA), remains an important complication of prematurity. Pulmonary inflammation plays a central role in the pathogenesis of BPD. Attenuating pulmonary inflammation wi... |
|
|
Nebulized corticosteroids in asthma and COPD. An Italian appraisal.
Respir. Care 57(7) , 1161-74, (2012) Inhaled corticosteroids (ICSs) are the mainstay of anti-inflammatory treatment in subjects with asthma and COPD. This review evaluates the role of nebulizers as an alternative to inhalers for delivering ICSs in asthma and COPD. I selected 16 randomized, place... |
|
|
Recurrent acute rhinosinusitis: a single blind clinical study of N-acetylcysteine vs ambroxol associated to corticosteroid therapy.
Int. J. Immunopathol. Pharmacol. 25(1) , 207-17, (2012) The aim of rhinosinusitis treatment is to restore sinusal eutrophism and to normalize ventilation and mucociliary transport. Frequently the improvement of sinusal physiological conditions is associated with a reduction of infections and pulmonary symptoms. Th... |
|
|
Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes.
Drug Metab. Dispos. 41(2) , 379-89, (2013) Asthma is one of the most prevalent diseases in the world, for which the mainstay treatment has been inhaled glucocorticoids (GCs). Despite the widespread use of these drugs, approximately 30% of asthma sufferers exhibit some degree of steroid insensitivity o... |
|
|
REDD1 functions at the crossroads between the therapeutic and adverse effects of topical glucocorticoids.
EMBO Mol. Med. 7(1) , 42-58, (2015) Cutaneous atrophy is the major adverse effect of topical glucocorticoids; however, its molecular mechanisms are poorly understood. Here, we identify stress-inducible mTOR inhibitor REDD1 (regulated in development and DNA damage response 1) as a major molecula... |
|
|
Comparison of a skin-lightening cream targeting melanogenesis on multiple levels to triple combination cream for melasma.
Journal. of. Drugs in. Dermatology. 12(3) , 270-4, (2013) The safety and efficacy of a novel skin-lightening cream (SLC) with 4% hydroquinone (HQ), which additionally contains 4 skin-brightening actives, was compared with a triple combination cream (TCC) with 4% HQ, 0.05% tretinoin, and 0.01% fluocinolone acetonide ... |